Model-Based Prediction of Acid Suppression and Proposal of a New Dosing Regimen of Fexuprazan in Humans

Fexuprazan is a potassium-competitive acid blocker (P-CAB). The compounds in this newly developed drug family suppress intragastric acidity. As there are already other acid-suppressing drugs on the market, such as H(2) antagonists and proton pump inhibitors (PPIs), it would be informative to compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Min-Soo, Lee, Nora, Lee, Areum, Chae, Yoon-Jee, Chung, Suk-Jae, Lee, Kyeong-Ryoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230547/
https://www.ncbi.nlm.nih.gov/pubmed/35745628
http://dx.doi.org/10.3390/ph15060709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230547/
https://www.ncbi.nlm.nih.gov/pubmed/35745628
http://dx.doi.org/10.3390/ph15060709

Ejemplares similares